Striatal dopaminergic D(2) receptor density measured by [(123)I]iodobenzamide SPECT in the prediction of treatment outcome of alcohol-dependent patients

Am J Psychiatry. 2000 Jan;157(1):127-9. doi: 10.1176/ajp.157.1.127.

Abstract

Objective: The authors' goal was to study striatal dopaminergic dopamine 2 (D(2)) receptors as a biological marker of early relapse in detoxified alcoholic patients by using [(123)I]iodobenzamide ([123I]IBZM) single photon emission computed tomography (SPECT).

Method: The authors performed [(123)I]IBZM SPECT on 21 alcohol-dependent inpatients during detoxification and on nine healthy volunteers, using the ratios of basal ganglia to occipital lobes for SPECT quantification. Depending on treatment outcome 3 months after hospital discharge, patients were determined to be relapsers or nonrelapsers.

Results: Alcohol-dependent subjects with early relapse (within 3 months after hospital discharge) showed a higher uptake of [(123)I]IBZM in the basal ganglia during detoxification (mean ratio=1.83, SD=0.9) than patients who did not have early relapse (mean ratio=1.69, SD=0.11).

Conclusions: These results suggest that low levels of dopamine, or an increased density of free striatal dopaminergic D(2) receptors, could be related to early relapse in alcohol-dependent patients. Therefore, [(123)I]IBZM SPECT could become a biological marker of vulnerability to relapse for alcoholic patients in recovery.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Alcoholism / diagnostic imaging*
  • Alcoholism / metabolism
  • Alcoholism / prevention & control*
  • Ambulatory Care
  • Basal Ganglia / diagnostic imaging
  • Basal Ganglia / metabolism
  • Behavior, Addictive / diagnostic imaging
  • Behavior, Addictive / metabolism
  • Behavior, Addictive / prevention & control
  • Benzamides
  • Biomarkers
  • Corpus Striatum / diagnostic imaging*
  • Corpus Striatum / metabolism
  • Female
  • Hospitalization
  • Humans
  • Iodine Radioisotopes
  • Male
  • Middle Aged
  • Probability
  • Pyrrolidines
  • Receptors, Dopamine D2 / metabolism*
  • Secondary Prevention
  • Tomography, Emission-Computed, Single-Photon*
  • Treatment Outcome

Substances

  • Benzamides
  • Biomarkers
  • Iodine Radioisotopes
  • Pyrrolidines
  • Receptors, Dopamine D2
  • 3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide